| Literature DB >> 34604590 |
Takuji Hinoura1, Shoichiro Mukai2, Toshiyuki Kamoto2, Yoshiki Kuroda1.
Abstract
INTRODUCTION: Prostate cancer (PCa) is one of the most common cancers affecting men globally. Although PER3 has been suggested as a risk factor for cancer development, there are few reports elucidating the relationship between PER3 and PCa. We investigated the association between PER3 polymorphisms (rs2640908 and VNTR) and susceptibility to PCa in the Japanese population.Entities:
Keywords: PER3; Polymorphism; Prostate cancer; Rs2640908; VNTR
Mesh:
Substances:
Year: 2021 PMID: 34604590 PMCID: PMC8451342 DOI: 10.15167/2421-4248/jpmh2021.62.2.1865
Source DB: PubMed Journal: J Prev Med Hyg ISSN: 1121-2233
Characteristics of the controls and cases.
| Variable | Controls (n = 122) | Cases (n = 83) | P-value |
|---|---|---|---|
|
| |||
| Mean (SD) | 69.2 (10.4) | 71.6 (8.6) | 0.08 |
|
| |||
| Never | 20 (16.4) | 27 (32.5) | 0.01 |
| Smoker | 102 (83.6) | 56 (67.5) | |
t-test and χ2 test were used for age and smoking status, respectively.
Associations between the PER3 genotype (rs2640908 and VNTR) and PCa.
| Genotype | Controls | Cases | Crude OR | Adjusted OR |
|---|---|---|---|---|
|
| ||||
| C/C (%) | 26 (21.3) | 29 (34.9) | Ref | Ref |
| C/T (%) | 63 (51.6) | 40 (48.2) | 0.57 (0.29-1.10) | 0.52 (0.26-1.03) |
| T/T (%) | 33 (27.0) | 14 (16.9) | 0.38 (0.16-0.85) | 0.35 (0.15-0.81) |
| C/T + T/T (%) | 96 (78.7) | 54 (65.1) | 0.50 (0.27-0.94) | 0.46 (0.24-0.88) |
|
| ||||
| 4/4 (%) | 82 (67.2) | 56 (67.5) | Ref | Ref |
| 4/5 (%) | 37 (30.3) | 25 (30.1) | 0.99 (0.53-1.82) | 0.94 (0.50-1.76) |
| 5/5 (%) | 3 (2.5) | 2 (2.4) | 0.98 (0.13-6.07) | 1.28 (0.16-8.69) |
| 4/5 + 5/5 (%) | 40 (32.8) | 27 (32.5) | 0.99 (0.54-1.79) | 0.96 (0.52-1.77) |
χ2 test and multiple logistic regression were used for crude OR and adjusted OR for age and smoking status, respectively. 95% CI: 95% confidence interval; OR: odds ratio; Ref: reference;
*: P < 0.05.
Associations between the PER3 genotype (rs2640908 and VNTR) and PCa when stratified by smoking status.
| Genotype | Controls | Cases | Crude OR | Adjusted OR |
|---|---|---|---|---|
|
| ||||
|
| ||||
| C/C (%) | 3 (15.0) | 8 (29.6) | Ref | Ref |
| C/T (%) | 11 (55.0) | 12 (44.4) | 0.41 (0.07-1.83) | 0.39 (0.07-1.76) |
| T/T (%) | 6 (30.0) | 7 (25.9) | 0.44 (0.07-2.34) | 0.53 (0.08-3.02) |
| C/T + T/T (%) | 17 (85.0) | 19 (70.4) | 0.42 (0.08-1.72) | 0.43 (0.08-1.79) |
|
| ||||
| 4/4 (%) | 12 (60.0) | 20 (74.1) | Ref | Ref |
| 4/5 (%) | 8 (40.0) | 6 (22.2) | 0.45 (0.12-1.60) | 0.40 (0.10-1.46) |
| 5/5 (%) | 0 (0) | 1 (3.7) | - | - |
| 4/5 + 5/5 (%) | 8 (40.0) | 7 (25.9) | 0.53 (0.15-1.81) | 0.48 (0.13-1.70) |
|
| ||||
|
| ||||
| C/C (%) | 23 (22.5) | 21 (37.5) | Ref | Ref |
| C/T (%) | 52 (51.0) | 28 (50.0) | 0.59 (0.28-1.25) | 0.57 (0.27-1.21) |
| T/T (%) | 27 (26.5) | 7 (12.5) | 0.28 (0.10-0.76) | 0.29 (0.10-0.77) |
| C/T + T/T (%) | 79 (77.5) | 35 (62.5) | 0.49 (0.24-0.99) | 0.47 (0.23-0.97) |
|
| ||||
| 4/4 (%) | 70 (68.6) | 36 (64.3) | Ref | Ref |
| 4/5 (%) | 29 (28.4) | 19 (33.9) | 1.27 (0.62-2.57) | 1.22 (0.60-2.48) |
| 5/5 (%) | 3 (2.9) | 1 (1.8) | 0.65 (0.03-5.27) | 0.81 (0.04-6.97) |
| 4/5 + 5/5 (%) | 32 (31.4) | 20 (35.7) | 1.22 (0.61-2.41) | 1.19 (0.59-2.37) |
χ2 test and multiple logistic regression were used for crude OR and adjusted OR for age, respectively. 95% CI: 95% confidence interval; OR: odds ratio; Ref: reference;
*: P < 0.05.